Teva Pharmaceutical Industries announces its U.S. launch of generic Axiron (testosterone) topical solution CIII, originally manufactured by Eli Lilly and Company.
Testosterone topical solution CIII is a prescription medicine used to treat adult males who have low
or no testosterone due to certain medical conditions. It is supplied in a metered dose pump with an
underarm applicator.
“We are pleased with the result in the district court, which has helped Teva add yet another product
to our industry-leading generic portfolio, providing savings to our customers and to patients,” said
Andy Boyer, Teva’s President and CEO, Global Generic Medicines, North America.
Axiron had annual sales of about $247 million in the U.S., according to IMS data as of May 2017.